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   Bladder cancer is one of the most frequent tumours of the urinary tract and the treatment of this 
malignancy requires close co-operation between urologists and oncologists. The superficial disease is 
treated with good results with transurethral resections and local immunotherapy or chemotherapy. 
However, there is a considerable fraction of BCG-refractory tumours (30%) and progression 
to muscle-invasive cancer. New approaches such as BCG combined with low-dose interferon 
or recombinant BCG strains are promising but need to be explored in prospective trials. Better 
understanding of the tumour biology and immunology will probably make it possible select patients 
with a high risk of progressive disease and to tailor further therapy options.  
The cornerstone of muscle invasive tumours treatment is radical cystectomy. The neoadjuvant 
chemotherapy is a promising option, especially in tumours invading deeply into the bladder wall 
or infiltrating the surrounding organs, but it require furthers confirmation of the results in phase III trials 
before introducing it as a standard treatment. However some leading centers have already 
implemented neoadjuvant chemotherapy in some selected groups of patients (eg. M.D. Anderson). 
Combined chemotherapy and modern 3-D conformal radiotherapy enable us to preserve the organ 
and the function of the bladder (bladder conserving therapy) and they are intensively studied in current 
trials.  
   In the near future molecular characterisation of individual tumours might help to choose a bladder 
conserving therapy or cystectomy adopted to a for particular patient. So far, four-drug regimen 
– MVAC has been widely used in metastatic and locally advanced disease. Recently, it was shown 
that a combination of gemcitabine and cisplatin (GC) is equally effective but less toxic. New chemo-
therapies tested in clinical trials include gemcitabine, taxanes and new-class drugs interfering with 
signal transduction. Individualization of established and experimental treatment options based on mo-
lecular tumour characteristics, such as p53 status will probably be the future of bladder cancer 
pharmacotherapy. 
 





   In the European Union countries cancer 
of the bladder accounts for about 7% of all 
cancers in men [1] and its incidence has 
been the increase in almost all European 
populations [2]. The difference in inci-
dence between sexes is mainly attributed 
to smoking habits and may also be asso-
ciated with exposure to some carcinogens 
in the environment [3]. In Poland in 1996 
bladder cancer was the fourth most 
frequent male cancer with 3070 new cases 
in men, accounting for 5,4% of all mali-
gnancies [4]. Mortality rates vary signi-
ficantly among European countries, 
especially low survival figures have been 
noted in some eastern European coun-
tries. In Poland in 1996 the overall 5-year 
survival in men was about 43%. This huge 
difference in survival may be attributed 
partially to a lower socio-economic status 
of Polish inhabitants compared with EU 
citizens (an association between depri-
vation and survival has been found 
for cancer in the bladder [5]). Another 
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important factor responsible for this situ-
ation might be the low popularity of adju-
vant treatment in superficial tumours and 
lack of strong cooperation between uro-
logists and oncologists resulting in a small 
proportions of patients receiving radio-
therapy or chemotherapy. 
 
SUPERFICIAL BLADDER CANCER 
 
   Superficial bladder cancer (Ta, Tis, T1) 
accounts for 70% to 80% of all bladder 
tumours. The recurrence rates after initial 
treatment range from 50 to 80%, with 
progression to a muscle-invading tumour 
in 10-25% [6,7]. Therefore, the prevention 
of recurrence and progression of the dise-
ase are the primary aims of treatment. 
The standard treatment consists of cysto-
scopic electroresection of the tumour 
(TURB) and adjuvant intravesical therapy 
in patients with a high risk of recurrence. 
Tis lesions, T1, and Ta high-grade (G3) 
tumours are associated with a high risk 
of recurrence and require adjuvant therapy 
to lower the risk of progression of the dise-
ase. 
   Adjuvant therapy is based on Bacillus 
Calmette-Guerin (BCG) or cytotoxic 
agents intravesical instillations. In Poland 
intravesical BCG therapy is less popular 
than in other European countries. BCG 
vaccine applied intravesicaly promotes 
inflammatory reaction in the bladder. Both 
the non-specific mechanisms mediated 
by NK cells (natural killer) and specific 
immune responses mediated by specific 
CTL (cytotoxic T lymphocytes) are enga-
ged in the elimination of tumour cells. 
BCG-therapy of superficial bladder cancer 
is so far the most efficient kind of cancer 
immunotherapy. The pros and cons 
of chemotherapy and BCG-therapy are 
summarised in table 1. BCG-therapy is 
more efficient than intravesical chemo-
therapy because it not only lowers the risk 
of local recurrence but also decreases 
the rate of progression to muscle invasive 
disease and improves survival [8,9]. 
The treatment options for BCG-refractory 
tumours are cystectomy, intravesical 
chemotherapy with traditional cytostatic 
drugs (therapy usually not efficient) or val-
rubicine. The use of “new agents” 
(IIIrd generation cytostatics) such as gem-
citabine, taxanes or valrubicin attract 
attention of many investigators. Valrubicin 
given over a 6-week course has been 
shown to be effective in ablating a marker 
tumour (complete histological regression) 
deliberately left in the bladder after 
incomplete TURB in 18 out of 39 patients 
with a refractory superficial disease [10]. 
Gemcitabine is also a widely tested 
compound and currently many phase 
I/II clinical trials currently under way 
around the world (Germany, Spain, 
Netherlands, USA, UK, Sweden, Israel) 
looking at optimal way to use gemcitabine 
in the treatment of the superficial disease. 
Results from these trials can be expected 
in the near future. Other studies put to test 
the hypothesis of enhancing the immuno-
stimulating effect of BCG therapy by intro-
ducing interferon-alfa2b or bropermine 
(interferon inducer). Salvage intravesical 
therapy with interferon-alpha2b plus a low 
dose BCG might be effective in patients 
with superficial bladder cancer in whom 
BCG alone has previously failed [11]. 
Another interesting investigational 
approach is the use of recombinant BCG 
strains that secrete cytokines such 
as GM-CSF, interferon gamma, IL-12 
or IL-2 [12]. IL-12 has several biological 
properties that seem useful in the immune 
therapy for bladder cancer. The significant 
antitumour responses with IL-12 in pre-
clinical animal models of bladder cancer 
are also promising [13].  
   The ability to genetically manipulate 
mycobacteria attracting attention because 
it makes it possible to enhance immuno-
genicity with lower doses and thus 
potentially prevent disseminated myco-
bacteriosis in the BCG-therapy in cancer 
patients [14]. Cell wall skeletons isolated 
from various bacteria have anticancer 
activity. Mycobacterial cell wall-DNA 
complexes (MCC) perform their action by 
induction cytokines and directly inducting 
apoptosis. The use of MCC for bladder 
and prostate cancer seems to be an inte-
resting option [15]. Another interesting 
approach to immunotherapy is based 
on dendritic cells. Dendritic cells are able 
to present tumour antigens to T cells very 
efficiently. Recently has been shown that 
autologous dendritic cells pulsed with 
MAGE-3 (tumour antigen expressed 
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in melanoma and other tumours) peptide 
are able to induce reduction of lymph node 
and liver metastases in three out of four 
bladder cancer patients [16].  
   It is now possible to distinguish between 
different types of immune responses 
to BCG in cancer patients by examining 
cytokine profile in the urine. Interleukin-2 
(IL-2) and interferon-gamma are released 
during T helper 1 lymphocyte responses, 
and IL-10 is released during T helper 
2 lymphocyte responses. T helper 1 lym-
phocyte urinary cytokine profile is asso-
ciated with a favourable prognosis after 
bacillus Calmette-Guerin (BCG) treatment. 
Urinary IL-2 levels may serve to identify 
patients at risk for bladder cancer 
recurrence after a single course of BCG 
and, thus, to tailor individual treatment 
[17,18]. The established prognostic factors 
such as grade, number and size of le-
sions, and resistance to BCG-therapy are 
too crude to precisely tailor therapy and 
follow-up policy to the individual patient 
who will frequently require cystectomy 
or radio/chemotherapy. Traditional diagno-
stic methods of local recurrence such as 
cystoscopy and cytological examination 
of the urine have limited sensitivity and 
specificity. The new methods of detecting 
tumour cells in urine are developed and 
tested mostly in small cohorts (dozens 
of patients), and the most promising 
of them deserve verification in the context 
of large randomized phase III trials. 
Another example of diagnostic tool is 
a microsatellite analysis DNA test 
in the urine which reliably signals the pre-
sence of recurrent bladder carcinoma, 
sometimes even before cystoscopic evi-
dence of recurrence. This non-invasive 
diagnostic tool has a potential to replace 
cystoscopy in many cases [19].  
   Cytogenetic analysis has provided 
strong evidence that loss of a suppressor 
gene or genes on chromosome 9 are 
frequently involved in the genesis of bla-
dder cancer. Mutations of the p53 tumour 
suppressor gene have been identified 
in 50% of high grade and advanced stage 
of bladder tumours, and are important 
in determining the clinical course of pa-
tients with superficial tumours and survival 
after neo-adjuvant chemotherapy [20,21]. 
Oncogenes of the ras gene family have 
been found in bladder cancer. A corre-
lation has been shown exist between 
the expression of ras protein and high 
histological grade. In addition, an asso-
ciation between c-myc oncoprotein expre-
ssion and recurrence or invasion in su-
perficial tumours has been shown. 
Methylation of the c-myc oncogene may 
also correlate with stage and grade. Flow 
cytometry may be helpful method for sta-
ging and planning treatment of bladder 
cancer in some cases. There appears 
to be a strong correlation between DNA 
content or ploidy and the level of diffe-
rentiation (tumour grade), depth of inva-
sion (tumour stage), and response to che-
motherapy. Flow cytometry results 
correlate with chromosomal changes. 
Progression and recurrence of tumours 
correlate with aneuploidy and an increase 
in the proliferative rate [22]. Aneuploidy 
may by detected in urine early, predicting 
recurrence [23].  
 
MUSCLE–INVASIVE AND LOCALLY 
ADVANCED BLADDER CANCER 
 
   The diagnosis of muscle invasive tumour 
(T2) or locally advanced bladder cancer 
(T3 to T4a) involves poorer prognosis. 
Only about 50% to 75% of patients with 
T2 stage disease survive 5 years and 
the proportion of survivors decreases with 
more advanced stages of the disease.  
   The therapy strategies for muscle-
invasive stage of the disease can be di-
vided into bladder sparing and non-
bladder sparing strategies. The first 
strategy of treatment is represented 
radical cystectomy, which is a standard 
treatment in muscle invasive tumours (T2) 
and T3a tumours. However, half of pa-
tients has micrometastases at the time 
of surgery. Recently, it has been shown 
that wide resection of the perivesical soft 
tissue and extended lymphadenectomy 
(to the bifurcation of aorta) provides 
the best chance for curing locally advan-
ced bladder cancer [24,25]. Thorough 
pelvic lymphadenectomy is indicated in all 
patients at the time of radical cystectomy, 
particularly if there no clinical evidence 
of nodal metastases [26]. Systemic 
treatment, administered before surgery 
(neoadjuvant) or after cystectomy (adju-
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vant) is still a matter of debate. A review 
of published randomised trials of adjuvant 
chemotherapy identified four trials with 
a total of only 278 patients [27]. In these 
trials the older standard chemotherapy 
regimens such as MVAC and CMV were 
used. However, the results appeared 
to show a significant difference in favour 
of adjuvant chemotherapy in three of them 
but serious methodological flows were 
reported in terms of sample size, early 
stopping rules, statistics and reporting 
results. Therefore the definitive value 
of adjuvant chemotherapy is still unclear 
and we are waiting to obtain results 
of the well-designed and well-conducted 
phase III trial.  
   Since gemcitabine with cisplatin has 
become a new standard regimen in me-
tastatic bladder cancer, this two-drug 
combination started to be used also 
in treatment of early stages of bladder 
cancer. MSKCC [28] runs a phase III study 
comparing gemcitabine and cisplatin 
(reference arm) with gemcitabine and 
doxorubicin combination (experimental 
arm). One of the major objectives 
of the trial is to determine if p53 and bcl-2 
protein expression are predictive factors 
for sur-vival of patients treated with these 
regimens. 
   For neoadjuvant therapy the situation is 
not evident as well because recently 
published two clinical phase III trials do not 
give the clear answer a question about 
the role of neoadjuvant chemotherapy. 
One of those is negative, the other posi-
tive, and the latter has been the subject 
of substantial criticism. In the larger 
EORTC-MRC trial 976 patients were 
assigned to three cycles of CMV chemo-
therapy (cisplatin, methotrexate, vinblas-
tine) or no chemotherapy before radical 
local treatment (cystectomy or radio-
therapy depending on the investigator’s 
and patient’s preference) [29]. 3-year sur-
vival advantage of 5,5% in favour of neo-
adjuvant chemotherapy (55,5% vs 50%) 
was not statistically significant (p=0.075) 
at the time of publication, however mature 
results presented at ASCO 2002 have 
shown statistically significant survival 
benefit. The projected 5-year survival rate 
with neoadjuvant CMV was 52%. 
Chemotherapy was associated with 
a 15% decrease in risk of death 
(HR=0,85 CI 0,71-1,02). In the exploratory 
subgroup analysis, greater effect of che-
motherapy was observed in the G3 sub-
group vs. (G1 and G2) and with the in-
creasing GFR (glomerular filtration rate). 
In conclusion authors of the study stated 
that these results do not justify the 
recommendation of neoadjuvant chemo-
therapy as standard treatment. However, 
they stressed several points that weaken 
the negative conclusion. In this trial broad 
category of patients, from cT2 to cT4a 
stage, was included, 34% were staged T2, 
in whom the benefit of adjuvant therapy 
may be less easy to demonstrate. The ad-
ministered chemotherapy might be sub-
optimal because it did not contain doxo-
rubicin. On the contrary, in the second 
major trial, primarily run by SWOG, 
neoadjuvant MVAC (methotrexate, vin-
blastine, adriamycin, cisplatin) followed 
by cystectomy was superior to cystectomy 
alone [30]. 15% gain in the 5-year overall 
survival (57% vs 42%, p=0,04) and nearly 
doubled median survival were observed 
(6,2 vs. 3,8 years). The third study from 
M.D. Anderson, addressed the issue 
of chemotherapy timing [31]. A total 
of 140 patients with locally advanced 
tumours (with lympho-vascular invasion 
on TUR or T3b-T4a) received two courses 
of MVAC followed by cystectomy and 
3 cycles of adjuvant MVAC or were treated 
initially with cystectomy followed by 5 cyc-
les of MVAC. There were no significant 
differences in outcome between two 
groups but impressively high survival 
results in this high risk cohort of patients 
(58% of patients remained disease free 
with median follow-up of 6,8 years) and 
better tolerability of neoadjuvant regimen 
supports the use of upfront chemotherapy 
in a high risk patients. The complete 
pathological remission after neoadjuvant 
chemotherapy appeared to be a strong 
positive prognostic factor for survival and 
this fact was confirmed by the results 
of both cited studies. The important issue 
is to show that expression of p53, bcl-2 
and others proteins may be helpful in se-
lecting patients for different neoadjuvant 
chemotherapy regimens because the ex-
pression pattern may be establish after 
initial endoscopic resection (biopsy) 
of the tumour tissue.  
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SPARING STRATEGIES OF TREAT-
MENT FOR MUSCLE-INVASIVE 
BLADDER CANCER 
 
   Another open question that remains 
to be answered is the potential of organ-
sparing therapy without cystectomy 
in locally advanced disease. In contrast 
to the USA and mostly of EU countries 
in Great Britain and Canada radiotherapy 
is a standard local treatment. The clinical 
efficacy of cystectomy and radical radio-
therapy has never been compared in head 
to head randomised trial. The survival 
figures are better in cystectomy series but 
one should bear in mind that groups 
treated with surgery and radiotherapy 
usually differed substantially. Patients 
in poor general condition are more often 
treated with radiotherapy than with 
surgery. Generally radiation therapy is 
reserved for patients who are medically 
unfit or who refuse surgery. Radiotherapy 
for patients with T2 to T4 stage of disease 
gives the probability of rendering the bla-
dder free of disease at 5 years in range 
from 35% to 45%, and overall survival 
from 23% to 40% [32]. In most cases, 
radiotherapy were delivered to a total dose 
of 55 to 65 Gy with daily dose of 2 Gy, but 
the optimal total dose and way of fra-
ctionation is under debate. Recently 
introduced, 3-D conformal radiotherapy 
(3D CRT) technologies enable to deliver 
required radiation dose to the target vo-
lume of tumour tissues with greater pre-
cision. It allows improving the therapeutic 
gain of radiotherapy due to better de-
lineation of target and improved protection 
of organs at risk (OAR). Another option 
of bladder-sparing strategy is radiotherapy 
combined with chemotherapy (concurrent 
or sequential), which is studied in several 
trials ongoing in Europe and in the USA 
[28]. Proponents of organ sparing therapy 
argue that radiotherapy combined with 
chemotherapy leaves room for cystectomy 
in case of local failure or initial lack 
of response after radio/chemotherapy [33]. 
There are not sufficient published data, 
which can support the introduction 
of bladder preservation therapy based 
on TURB with following by concurrent 
radio-chemotherapy.  
   Partial cystectomy represents an option 
of sparing approach for small, low grade 
solitary tumour which is located away from 
the bladder neck and trigone, and for older 
patients who are not good candidates 
for total cystectomy. Since the rate of local 
recurrence is high after partial cystectomy 
(30% - 70%) this strategy is not generally 
accepted as a sole method of treatment 
and usually is combined with neoadjuvant 
chemotherapy [34]. However, no clinical 
data have demonstrated so far a survival 
benefit due to application of neoadjuvant 
chemotherapy.  
 
METASTATIC DISEASE  
    
   Generally bladder cancer is a chemo-
therapy sensitive disease and multi-agent 
therapy is more effective. MVAC regimen, 
developed at MSKCC was considered as 
the treatment of choice for the last decade. 
Unfortunately, high response rates (70%) 
attained with MVAC chemotherapy were 
associated with very few long- term sur-
vivors (3-5% at 5-year follow-up) and with 
substantial toxicity. Toxic deaths occurred 
in 3% to 4% of patients, neutropenic fever 
and sepsis in 20% to 30%, severe 
mucositis in 10% to 20%. Van der Maase 
et al. published in 2000 results of the 
randomised trial comparing MVAC to GC 
(gemcitabine-cisplatin) combination, which 
established a new standard chemotherapy 
regimen [35]. 405 patients with stage T4b 
or with metastatic disease were rando-
mised to GC (gemcitabine 1000 mg/m2, 
days 1,8 and 15; cisplatin 70mg/m2, day2) 
or standard MVAC. Overall survival, time 
to treatment failure, time to progressive 
disease and response rate were very 
similar in both arms but safety profile and 
tolerability of GC regimen was superior. 
The toxic deaths rate was 1% on the GC 
arm, 3% on the MVAC arm, the neutro-
penic fever rate was 2% in GC group, 
14% in the MVAC group, neutropenic 
sepsis was observed in only 1% of pa-
tients treated with GC and in 12% 
of MVAC-treated patients, mucositis in 1% 
of GC and in 22% of MVAC patients. 
Seven of the eight deaths were related 
to complications of neutropenia and one 
to complication of mucositis. The authors 
concluded that GC chemotherapy is a sa-
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fer alternative to MVAC and should be 
considered the standard of care for locally 
advanced and metastatic patients and 
the potential of GC regimen should be 
investigated in earlier stages of the dise-
ase. 
   Since toxicity of MVAC chemotherapy 
was largely due to complications of neutro-
penia colony stimulating factors (G-CSF, 
GM-CSF) support was used to ameliorate 
the unfavourable toxicity profile. Sternberg 
et al. made a step forward and compare 
intensified MVAC (i-MVAC) regimen with 
G-CSF support with a standard MVAC. 
Recently published results of this trial 
showed that the support of G-CSF 
enabled to deliver twice higher doses 
of cisplatin and doxorubicin, with less 
toxicity as compared to the treatment 
without G-CSF [36]. A statistically signi-
ficant benefit was observed in progre-
ssion-free survival and response rates but 
not in overall survival or time to progre-
ssion. 
   Above mentioned data demonstrates 
that gemcitabine and cisplatin regimen has 
high efficacy together with good tolerability 
and can be used for wider spectrum of pa-
tients. On the other hand intensified MVAC 
regimen administered with G-CSF has 
acceptable toxicity, but outcome of the pa-
tients remain practically unchanged. With 
this respect it’s questionable whether 
prescription of expensive growth factors 
with intensified MVAC is worthy, even 
for fit patients. 
 
FUTURE STRATEGIES IN TREATMENT 
OF BLADDER CANCER 
 
   Preclinical cancer models have 
demonstrated that the delivery of p53 
gene to tumour cells by viral or non-viral 
gene transfer methods resulted in enhan-
ced sensitivity to cytotoxic drugs or radio-
therapy. Recently a successful adeno-
virus-mediated p53 gene transfer to the 
bladder tumours in patients with muscle-
invasive disease have been reported. 
Safe, practicable gene transfer (intra-
vesical instillation), and biological activity 
of p53 shown in this study provide a strong 
rationale for future phase II and III studies 
in patients with superficial high-risk 
bladder cancer [37]. Since BCG is 
the most efficient in superficial disease we 
may expect that different modifications 
such as genetically altered BCG-strains, 
cytokine secreting bacteria or cell wall 
extracts will be studied in BCG-refractory 
superficial disease. 
   Progress in chemotherapy of bladder 
cancer can be made with both introducing 
new drug combinations and new sche-
dules of sequential chemotherapy. New 
regimens active in bladder cancer tested 
in clinical trials contain gemcitabine and 
taxane with or without cisplatin or a new-
class drug such as inhibitor of signal 
transduction via EGFR (epithelial growth 
factor receptor) such as trastuzumab 
or ZD 1839 [28]. The ongoing largest 
phase III study is conducted by several 
American and European co-operative 
groups together (trial co-ordinated by 
EORTC, planned accrual 610 patients 
during 3 years) is comparing GC regimen 
with GC plus paclitaxel. At the same time 
unfit patients with compromised renal 
function are enrolled onto the EORTC trial 
comparing gemcitabine plus carboplatin 
vs. carboplatin, methotrexate and vin-
blastine. New schedules are based on 
the Norton and Simon hypothesis of maxi-
mising individual drugs or combinations 
of agents devoid of overlapping toxicity. 
In MSKCC phase III trial is run in which 
patients are receiving doxorubicin and 
gemcitabine followed by paclitaxel and cis-
platin vs. adjuvant cisplatin and gemci-
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